Details of PSA and PSAP immunostaining methods
| Pretreatment method (N (%)) | |||||||
|---|---|---|---|---|---|---|---|
| Antibody | N (%) | None | Enzyme | Heat | Enzyme + heat | Not indicated | |
| *One centre used both monoclonal and polyclonal antibodies to PSA. | |||||||
| PSA, prostate specific antigen; PSAP, prostate specific acid phosphatase. | |||||||
| UK laboratories (n = 133) | |||||||
| Monoclonal anti-PSA | 53 (40%) | 16 (30%) | 5 (9%) | 31 (59%) | 0 | 1 (2%) | |
| Polyclonal anti-PSA | 80 (60%) | 40 (50%) | 19 (24%) | 20 (25%) | 0 | 1 (1%) | |
| Monoclonal anti-PSAP | 38 (29%) | 16 (42%) | 1 (3%) | 18 (47%) | 0 | 3 (8%) | |
| Polyclonal anti-PSAP | 36 (27%) | 21 (58%) | 7 (19%) | 8 (22%) | 0 | 0 | |
| Non-UK laboratories (n = 87) | |||||||
| Monoclonal anti-PSA | 45 (52%)* | 14 (31%) | 1 (2%) | 27 (60%) | 2 (4%) | 1 (2%) | |
| Polyclonal anti-PSA | 43 (49%)* | 23 (54%) | 2 (5%) | 17 (40%) | 0 | 1 (2%) | |
| Monoclonal anti-PSAP | 31 (36%) | 13 (42%) | 0 | 18 (58%) | 0 | 0 | |
| Polyclonal anti-PSAP | 15 (17%) | 11 (73%) | 0 | 4 (27%) | 0 | 0 | |